ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,374.00
-0.06%
S&P ASX All Technology
3,953.80
1.34%
Brent Oil
76.175
1.08%
US Dollar vs AUD
1.59899
-0.58%
Bitcoin
99,105.16
-2.28%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Carisma Therapeutics Inc (CARM) Share Price

Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

Carmanah Minerals Corp
Carrefour Property Development
0.4729
0.0159
( 3.48% )
Updated: 05:09:12
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.4729
Bid
0.45
Offer
0.4705
Volume
232,873
0.4433 Day's Range 0.4765
0.38 52 Week Range 2.77
Market Cap
19.744M
Previous Close
0.457
Open
0.4433
Last Trade
1
@
0.4527
Last Trade Time
04:59:30
Financial Volume
US$ 107,773
VWAP
0.462798
Average Volume (3m)
389,648
Shares Outstanding
41,750,109
Dividend Yield
-
PE Ratio
-0.23
Earnings Per Share (EPS)
-2.08
Revenue
14.92M
Net Profit
-86.88M

About Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.carismatx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was US$0.46. Over the last year, Carisma Therapeutics shares have traded in a share price range of US$ 0.38 to US$ 2.77.

Carisma Therapeutics currently has 41,750,109 shares in issue. The market capitalisation of Carisma Therapeutics is US$19.08 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.23.

Ask ADVFN Intelligence (AI)

CARM Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

31 January 2025
Edgar (US Regulatory)

Carmila : Moyens portés au contrat de liquidité au 31 décembre 2024

Regulatory News: Au titre du contrat de liquidité confié par Carmila (Paris:CARM) à Kepler Cheuvreux, au 31 décembre 2024, les ressources mises à disposition du contrat de liquidité étaient les...

15 January 2025
Business Wire

Form 8-K - Current report

13 January 2025
Edgar (US Regulatory)

Form 8-K - Current report

11 January 2025
Edgar (US Regulatory)

Carmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market Close

Regulatory News: Carmila (Paris:CARM) will publish its 2024 full-year results on Tuesday, February 11, 2025, after market close and will present the 2024 full-year results on Wednesday, February...

10 January 2025
Business Wire

Form 3 - Initial statement of beneficial ownership of securities

03 January 2025
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0403-7.852689010130.51320.51320.41514686930.49963668CS
4-0.1061-18.32469775470.5790.61790.4155651170.49412794CS
12-0.5271-52.7111.01050.383896480.54212035CS
26-0.4571-49.15053763440.931.260.382585100.69706508CS
52-1.6371-77.58767772512.112.770.382722581.14830186CS
156-5.3171-91.83246977555.799.76620.382514572.8976987CS
260-5.3171-91.83246977555.799.76620.382514572.8976987CS

CARM - Frequently Asked Questions (FAQ)

What is the current Carisma Therapeutics share price?
The current share price of Carisma Therapeutics is US$ 0.4729
How many Carisma Therapeutics shares are in issue?
Carisma Therapeutics has 41,750,109 shares in issue
What is the market cap of Carisma Therapeutics?
The market capitalisation of Carisma Therapeutics is USD 19.08M
What is the 1 year trading range for Carisma Therapeutics share price?
Carisma Therapeutics has traded in the range of US$ 0.38 to US$ 2.77 during the past year
What is the PE ratio of Carisma Therapeutics?
The price to earnings ratio of Carisma Therapeutics is -0.23
What is the cash to sales ratio of Carisma Therapeutics?
The cash to sales ratio of Carisma Therapeutics is 1.32
What is the reporting currency for Carisma Therapeutics?
Carisma Therapeutics reports financial results in USD
What is the latest annual turnover for Carisma Therapeutics?
The latest annual turnover of Carisma Therapeutics is USD 14.92M
What is the latest annual profit for Carisma Therapeutics?
The latest annual profit of Carisma Therapeutics is USD -86.88M
What is the registered address of Carisma Therapeutics?
The registered address for Carisma Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Carisma Therapeutics website address?
The website address for Carisma Therapeutics is www.carismatx.com
Which industry sector does Carisma Therapeutics operate in?
Carisma Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPTCaptiVision Inc
US$ 1.275
(190.43%)
204.22M
LTRYLottery com Inc
US$ 0.5445
(74.52%)
82.14M
QNTMQuantum Biopharma Ltd
US$ 5.31
(66.98%)
48.38M
NVVENuvve Holding Corporation
US$ 4.0028
(51.05%)
3.27M
PTIRGraniteShares 2X Long PLTR Daily ETF
US$ 219.35
(41.23%)
1.5M
OMGAOmega Therapeutics Inc
US$ 0.2151
(-55.10%)
3.8M
TOIIWOncology Institute Inc
US$ 0.021
(-46.43%)
171
VIRXViracta Therapeutics Inc
US$ 0.0512
(-34.19%)
3.86M
UPCUniverse Pharmaceuticals Inc
US$ 0.2817
(-32.51%)
1.3M
CYNCYNGN Inc
US$ 0.0835
(-28.57%)
55.88M
CAPTCaptiVision Inc
US$ 1.279
(191.34%)
204.23M
PLTRPalantir Technologies Inc
US$ 101.115
(20.75%)
152.82M
NVDANVIDIA Corporation
US$ 118.2588
(1.37%)
143.73M
RGTIRigetti Computing Inc
US$ 13.7399
(2.00%)
118.29M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1578
(-19.04%)
86.01M

CARM Discussion

View Posts
glenn1919 glenn1919 6 days ago
CARM...................................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 4 months ago
I appreciate you reaching out. I like to follow the money in bioland or predict where it might go. Hence i really like this. Their CAR M CD47 approach is not new and many wished for these trials. The risk however is huge hence no one bit this (monotherapy trial with safety as primary endpoint is almost random)

I am having a very close eye on this as they will share the first clinical data in q4. Any price increase prior might hint at things being right/a rally coming. The problem is, this is monotherapy only and not the one where they combine with the mRNA tech (which is likely where the good stuff is)

So down the road we will be getting some great hints here on whether this might be "THE next big thing" or not.... A LOT of targets nominated by them...
👍️0
jondoeuk jondoeuk 5 months ago
From this: “Without a doubt there's big biological risk here,” says Carisma CSO Michael Klichinsky. Researchers have yet to prove either the efficacy or the approvability of CAR macrophages. But solid tumours account for 90% of the cancer burden, making the possibility of activity in these settings with an in vivo reprogramming agent all the more appealing. “We’re going after a real unmet need,” he adds. https://www.nature.com/articles/d41573-024-00150-z
👍️0
Prestotic Prestotic 5 months ago
Vdog, your dog stock shedding another 8.33% today on a pathetic 2 million shares. Going to trips withou a contract soon. Hope you get this message. You could be in Carisma if only you listened.
👍️0
Prestotic Prestotic 5 months ago
Vdog has no Carisma Therapeutics. Losers like him love losers like VXIT. Carisma up 50 % in 2 weeks, Vxit down 50%. LOVE to say I TOLD YOU SO! How's your DD treating you JA
👍️0
Prestotic Prestotic 5 months ago
Eat shi* vdog
👍️0
Prestotic Prestotic 6 months ago
Another 50,000 getting accumulated/ covered @ $1.04. To the moon, soon.
👍️0
Prestotic Prestotic 6 months ago
No noise here because Carisma is not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid June. Today's action, including buy, buy, buy of 75000 shares at 3:30 pm shows accumulation, or at least some worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
Prestotic Prestotic 6 months ago
No noise here because Carisma in not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid July. Today's action, including buy, buy, buy of 75000 shares around 2pm shows accumulation, or at least something worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
CancunCharlie CancunCharlie 6 months ago
Is there anyone here?? No comments in over a month. I think this looks good, but I'm wondering why it's so quite here.
👍️0
PonkenPlonken PonkenPlonken 7 months ago
pretty strong
nice tech$
👍️0
glenn1919 glenn1919 7 months ago
CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 7 months ago
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
👍️0
Termite7 Termite7 8 months ago
Could it be CARM under $0.30 ....???.......Thanks!!!
👍️0
axelvento axelvento 9 months ago
$1.46 bouncer
👍️0
PonkenPlonken PonkenPlonken 10 months ago
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
👍️0
Monksdream Monksdream 10 months ago
CARM under $3
👍️0
mrplmer mrplmer 1 year ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
mrplmer mrplmer 1 year ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
81vette 81vette 1 year ago
1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
👍️0
81vette 81vette 1 year ago
Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
👍️0
stock1ace1 stock1ace1 1 year ago
Red on news .. we no what that means lol
👍️0
81vette 81vette 1 year ago
Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
👍️0

Your Recent History

NASDAQ
CARM
Carisma Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads